SAFETY OF BMS 186716 IN THE TREATMENT OF HEART FAILURE
University Of Utah, Salt Lake City UT
Investigators
Linked publications & trials
Abstract
This multi-institutional, category D study has been completed. The study drug is a selective competitive inhibitor of neutral endopeptidase and angiotensin-converting enzyme. Inhibition of neutral endopeptidase prevents enzymatic inactivation of atrial naturetic peptide and brain naturetic peptide, potentiating diuretic and vasodilatory effects. Since angiotensin-converting enzyme inhibition increases circulating renin, neutral endopeptidase may antagonize this effect by causing an increase in atrial naturetic peptide, which inhibits renin secretion. Data collected on this study was forwarded to the industrial sponsor. Results of the study will be made available after data from all participating centers has been analyzed.
View original record on NIH RePORTER →